This is a cohort study on HIV-1 patients treated in outpatient and inpatient wards of Tangerang District Hospital. The participant will be interviewed and retrieved for their demographics, treatment history, CD4 and viral load history. Blood will be drawn for HIV-1 viral load examination using Xpert® HIV-1 Viral Load \[Cepheid\], in-house qRT-PCR, and REALTIME HIV-1 VIRAL LOAD \[Abbott\]
Participant candidate will be screened at Tangerang District Hospital's outpatient and inpatient units. The purpose is to get various VL values from participants with various clinical conditions (light-heavy). If a participant is willing to participate and has signed the Informed Consent Form (ICF), he/she will be interviewed for demographic data and case history (age, gender, first HIV diagnosis). After that, the participant will be physically examined (height, weight, and vital signs). Other information, such as current HIV clinical stage, current ART regimen, Viral Load value (final and highest), and CD4 (final and lowest) are collected from participant's medical records. The participant's blood will be drawn as much as 9 ml and will be processed to obtain plasma. Plasma will be aliquoted into 3 vials for VL test using 3 devices: 1 ml using Xpert HIV-1, 1 ml using PCR (Abbott) at Dharmais Hospital, and 1 ml or leftover plasma using PCR (ABI7500) at INA-RESPOND's reference laboratory. The process follows the manufacturer's manual or the standard of sample preparation procedure and the operation of the devices at each hospital. The result of viral load measurement will be informed to the participant via the attending physician during the participant's routine HIV treatment visit to the hospital.
Study Type
OBSERVATIONAL
Enrollment
58
RSU Kabupaten Tangerang
Tangerang, West Java, Indonesia
To evaluate the performance of three different methods in measuring HIV-1 VL.
HIV-1 RNA concentration (copies/ml) is determined from three different plasma viral load (pVL) measurement: Xpert® HIV-1 Viral Load \[Cepheid\], in-house qRT-PCR observing a conserved region in HIV-1 gag gene (HXB2 1849-1896) \[primer/probes: Palmer S, Wiegand AP, Maldarelli F, et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol. 2003 Oct;41(10):4531-6. doi: 10.1128/JCM.41.10.4531-4536.2003. PMID: 14532178; PMCID: PMC254331\], and REALTIME HIV-1 VIRAL LOAD \[Abbott\].
Time frame: From date of patient enrolment until the date of completed result analysis for three assays, which is estimated for four (4) months.
To evaluate correlation of HIV-1 pVL measurement using Xpert® HIV-1 Viral Load [Cepheid] and in-house qRT-PCR [HIV-1 gag gene (HXB2 1849-1896), Palmer S, Wiegand AP, Maldarelli F, et al. J Clin Microbiol. 2003 Oct;41(10):4531-6]
Mean difference of HIV-1 RNA concentration.
Time frame: From date of patient enrolment until the date of completed result analysis for three assays, which is estimated for four (4) months.
To evaluate correlation of HIV-1 pVL measurement using Xpert® HIV-1 Viral Load [Cepheid] and REALTIME HIV-1 VIRAL LOAD [Abbott].
Mean difference of HIV-1 RNA concentration.
Time frame: From date of patient enrolment until the date of completed result analysis for three assays, which is estimated for four (4) months.
To evaluate correlation and mean difference in HIV-1 pVL measurement using REALTIME HIV-1 VIRAL LOAD [Abbott] and in-house qRT-PCR [HIV-1 gag gene (HXB2 1849-1896), Palmer S, Wiegand AP, Maldarelli F, et al. J Clin Microbiol. 2003 Oct;41(10):4531-6].
Mean difference of HIV-1 RNA concentration.
Time frame: From date of patient enrolment until the date of completed result analysis for three assays, which is estimated for four (4) months.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.